DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/t4jthl/brain_cancer_drug) has announced the addition of the "Brain Cancer Drug Pipeline Update 2015" report to their offering.
Despite the heavy investment made into brain cancer research, primary brain cancer, with glioblastoma multiforme being the most aggressive and most common form, remains one of the most deadly diseases in the developed world. While primary brain tumors are relatively rare, the chances of survival for patients with the disease are very low, even with the best treatment options currently available.
There are today 224 companies plus partners developing 276 drugs targeting brain cancer in development. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 93 drugs. Brain Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 201 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer.
To date 193 out of the 195 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 53 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Pipeline Breakdown According to Number of Drugs
- Marketed - 12
- Pre-registration - 1
- Phase III - 11
- Phase II - 130
- Phase I - 53
- Preclinical - 61
- No Data - 8
- Suspended - 2
Ceased - 93
For more information visit http://www.researchandmarkets.com/research/t4jthl/brain_cancer_drug